2012年丙型肝炎领域的研究进展被引量：1

What is new in 2012 on hepatitis C

导出

摘要 2012年丙型肝炎研究方面突破性的进展主要是对直接抗病毒药物（direct acting anfiviral agents，DAAs）临床研究的进展以及对聚乙二醇干扰素Ⅸ（Peg-IFNa）联合利巴韦林（fibavirin，RaY）传统标准治疗的再研究。

作者魏来

机构地区北京大学人民医院北京大学肝病研究所

出处《中华肝脏病杂志》 CAS CSCD 北大核心 2013年第3期164-166,共3页 Chinese Journal of Hepatology

关键词肝炎丙型治疗直接抗病毒药物 Hepatitis C Therapy Direct acting antivimlagents

分类号 R512.63 [医药卫生—内科学]

引文网络
相关文献

参考文献14

1Poordad F, Fried MW, Zeuzem S, et al. Efficacy and tolerability of simeprevir (TMC435) 150 mg once daily with peginterferon alfa-2a and ribavirin for treatment of HCV genotype 1 infection in patients with Metavir score F3 and F4 (PILLAR and ASPIRE trials). Hepatology, 2012, 56 Suppl 1: 233A.
2Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6:TMC435-C202, a phase IIa, open-label study. J Hepatol, 2012, 56: 1247-1253.
3Lok AS, Gardincr DF, Lawitz E, ct al. Preliminary study of two antiviral agents for hepatitis C gcnotypc I. N Engl J Med, 2012, 366: 216-224.
4Gane E J, Stedman CA, Hyland RH, et al. Electron: once daily GS- 7977 plus ribavirin in HCV genotypes 1-3. J Hepatol, 2012, 56 Suppl 2: $438-439.
5Zeuzem S, Soriano V, Asselah T, et al. Interferon (IFN)-free combination treatment with the HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NSSB inhibitor BI 207127 + ribavirin (R): final results of SOUND-C2 and predictors of response. Hepatology, 2012, 56 Suppl l: 308A.
6Soriano V, Gane E, Angus P, et al. Efficacy and safety of the interferon (IFN)-free combination of BI 201335 + BI 207127 :i: ribavirin (RBV) in treatment-naive patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: results from the SOUND-C2 study. Hepatology, 2012, 56 Suppl 1: 234A.
7McPhee F, Sheaffer AK, Friborg J, et al. Preclinieal profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother, 2012, 56: 5387-5396.
8Izumi N, LaTaillade M, Chayama K, et al. First report of peginterferon lambda/ribavirin in combination with either daclatasvir or asunaprevir in HCV genotype 1 Japanese subjects: early sustained virologic response (SVR4) results from the D-LITE Japanese substudy. Hepatology, 2012, 56 Suppl 1:310A.
9Cheinquer H, Shiffman ML, Zeuzem S, et al. The outcome of 24 vs 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study. Hepatulogy, 2012, 56 Suppl l: 271A.
10Liu CH, Liang CC, Su TH, et al. Peginterferon alfa-2a plus low dose ribavirin versus pegintfferon alfa-2a monotherapy for dialysis patients with hepatitis C virus ganotype 1 infection: a randomized trial. Hepatology, 2012, 56 Suppl 1: 993A.